

Translation

PATENT COOPERATION TREATY

PCT


INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 04 AUG 2004

WIPO

PCT

Applicant's or agent's file reference 03004CP		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/CN03/00213	International filing date (day/month/year) 25. Mar.2003 (25. 03. 03)	Priority date (day/month/year) 2. Apr.2002 (02. 04. 02)	
International Patent Classification (IPC) or national classification and IPC IPC 7 C07D277/22 277/38 263/30 263/48 207/30 207/34 401/12 403/12 405/12 407/12 417/12 A61K31/40 31/41			
Applicant SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES etc.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 4 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and /or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 7 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report</p> <p>II <input type="checkbox"/> priority</p> <p>III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty ,inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2)with regard to novelty ,inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application.</p>			
Date of submission of the demand 03. Nov., 2003(03. 11. 03)		Date of completion of this report 30 June, 2004(30.06.2004)	
Name and mailing address of the IPEA/CN 6 Xitucheng Rd., Jimen Bridge, Haidian District, 100088 Beijing, China Facsimile No. 86-10-62019451		 Authorized officer Zhou Huijun Telephone No. (010) 62085633	

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/CN01/00213

I. Basis of the report

1. With regard to the elements of the international application:

☐ the international application as originally filed☒ the description:

pages 1,2,5-13

,as originally filed

pages 3/1, 3/2, 4/1, 4/2

,filed with the demand

pages _____,filed with the letter of _____

☒ the claims:

Nos _____,as originally file

Nos _____, as amended (together with any statement)under Article 19

Nos 1-11 _____,filed with the demand

Nos _____,filed with the letter of _____

☐ the drawings:

sheets/fig _____,as originally filed

sheets/fig _____,filed with the demand

sheets/fig _____,filed with the letter of _____

☐ the sequence listing part of the description:

pages _____,as originally filed

pages _____,filed with the demand

pages _____,filed with the letter of _____

2. with regard to the language,all the elements marked above were available or furnished to this Authority in the language in which the international application was filed,unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application(under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application,the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.☐ filed together with the international application in computer readable form.☐ furnished subsequently to this Authority in written form.☐ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4. ☐ The amendments have resulted in the cancellation of:☐ the description,pages _____☐ the claims No. _____☐ the drawings,sheets/fig _____5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments(Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. This questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of :

☐ the entire international application,

☒ claims Nos. 1-11 (X=O, N)

because:

☐ the said international application, or the said claims Nos. _____

relate to the following subject matter which does not require an international preliminary examination (specify):

☐ the description, claims or drawings (indicate particular elements below) or said claims Nos. _____
are so unclear that no meaningful opinion could be formed (specify):

☐ the claims, or said claims Nos. _____ are so inadequately supported
by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claims Nos. 1-11 (X=O, N).

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement:**

Novelty (N)

Claims 1-11

YES

Claims

NO

Inventive step (IS)

Claims 1-11

YES

Claims

NO

Industrial applicability (IA)

Claims 1-11

YES

Claims

NO

2. Citations and explanations (Rule 70.7)

Claims 1-11 are novel over D1-D3.

D1 discloses compounds which are different from the compounds of the invention, though they act as inhibitors of methionine aminopeptidase as well; And D2 and D3 disclose compounds which are quite similar in structure to the compounds of the invention, but they are useful as fungicides. So the compounds of the invention, with the activity for inhibiting methionine aminopeptidase, would not be considered to be obvious to the skilled person.

Claims 1-11 seem to meet the criteria set out in PCT Article 33(2)-(4) regarding to novelty, inventive step and industrial applicability.

第VIII(iii)栏 声明：有权要求优先权

声明必须与规程 213 条的标准语句一致：参见对于 VIII、VIII(i) 到(v) (概述) 的说明和专门对于 VIII(iii) 的说明。如果不使用本栏，则请求书中不应包括此页。

关于申请人在国际申请日有权要求下面指明的在先申请优先权的声明，如果该申请人不是在先申请的申请人，或在提交在先申请后申请人的姓名进行了变更。(细则 4.17(iii)和 51 之二.1(a)(iii)):

关于本国际申请:

中国科学研究院上海药物研究所基于下列事项，有权要求申请号为 02111230.4 的在先申请的优先权:

中国科学研究院上海药物研究所作为发明人南发俊、叶其壮、李静雅、刘志英、罗群力、崔永梅的雇主是有权的;

本声明是对除美国以外的所有指定国的。

关于本国际申请:

南发俊、叶其壮、李静雅、刘志英、罗群力、崔永梅基于下列事项，有权要求申请号为 02111230.4 的在先申请的优先权:

南发俊、叶其壮、李静雅、刘志英、罗群力、崔永梅是通过在先申请寻求保护的主题的发明人;

本声明是对下列为获得国家专利和/或地区专利的指定国的：美国。

☐ 本声明下转声明续页中“续第 VIII (iii) 栏”。